However, rofecoxib, a selective COX2 inhibitor, did not show any effect on tumor recurrence in PIK3CA mutant CRC patients, suggesting that other, non-COX2-related mechanisms of action of aspirin might play a relevant role in its protective effect [102]. The gene discussed is PIK3CA; the disease is neoplasm.